LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 3399 | 5013 | 0.6780 | 0.5639 |
MDA-MB-231 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 1311 | 1207 | 5013 | 0.2409 | -0.0281 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 759 | 5013 | 0.1514 | -0.1493 |
MDA-MB-231 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 606 | 5013 | 0.1210 | -0.1905 |
MDA-MB-231 | CHIR-99021 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 4289 | 5013 | 0.8556 | 0.8045 |
MDA-MB-231 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4638 | 5013 | 0.9252 | 0.8987 |
MDA-MB-231 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4685 | 5013 | 0.9345 | 0.9113 |
MDA-MB-231 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 2206 | 5013 | 0.4400 | 0.2416 |
MDA-MB-231 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 2876 | 5013 | 0.5737 | 0.4226 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 956 | 5013 | 0.1908 | -0.0959 |
MDA-MB-231 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 874 | 5013 | 0.1745 | -0.1181 |
MDA-MB-231 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 2456 | 5013 | 0.4900 | 0.3093 |
MDA-MB-231 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4917 | 5013 | 0.9808 | 0.9739 |
MDA-MB-231 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4951 | 5013 | 0.9876 | 0.9832 |
MDA-MB-231 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 1311 | 1321 | 5013 | 0.2636 | 0.0027 |
MDA-MB-231 | R406 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 3261 | 5013 | 0.6504 | 0.5266 |
MDA-MB-231 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 3377 | 5013 | 0.6736 | 0.5579 |
MDA-MB-231 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 4967 | 5013 | 0.9907 | 0.9874 |
MDA-MB-231 | Geldanamycin | 3.33 | uM | LJP5 | 72 | hr | 1311 | 928 | 5013 | 0.1852 | -0.1036 |
MDA-MB-231 | Geldanamycin | 3.33 | uM | LJP6 | 72 | hr | 1311 | 874 | 5013 | 0.1743 | -0.1182 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 1914 | 5013 | 0.3818 | 0.1627 |
MDA-MB-231 | GSK1059615 | 3.33 | uM | LJP6 | 72 | hr | 1311 | 3119 | 5013 | 0.6222 | 0.4883 |
MDA-MB-231 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1311 | 4775 | 5013 | 0.9524 | 0.9356 |
MDA-MB-231 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 1311 | 888 | 5013 | 0.1771 | -0.1145 |
MDA-MB-231 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1311 | 4949 | 5013 | 0.9872 | 0.9827 |